Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

Julia A Gaebler1, Gerardo Soto-Campos2, Peter Alperin2, Marc Cohen2, Amy Blickensderfer1, Matthew Wintle1, David Maggs1, Byron Hoogwerf3, Jenny Han1, Richard Pencek1, Barbara Peskin21Amylin Pharmaceuticals, Inc, San Diego CA, 2Archimedes Inc, San Francisco CA, 3Eli Lilly and Company, Indianapolis, I...

Full description

Bibliographic Details
Main Authors: Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B
Format: Article
Language:English
Published: Dove Medical Press 2012-04-01
Series:Vascular Health and Risk Management
Online Access:http://www.dovepress.com/health-and-economic-outcomes-for-exenatide-once-weekly-insulin-and-pio-a9747

Internet

http://www.dovepress.com/health-and-economic-outcomes-for-exenatide-once-weekly-insulin-and-pio-a9747

Similar Items